NEWS:Maricopa Medical Center Selects CDEX's ValiMed Technology for End Product Testing
Wednesday October 12, 1:00 pm ET
ROCKVILLE, Md. & PHOENIX--(BUSINESS WIRE)--Oct. 12, 2005--CDEX Inc. (OTCBB:CEXI - News) announces that Maricopa Medical Center in Phoenix, Arizona, has selected the CDEX ValiMed Patient Safety Solution to do end product testing of compounded IV medications in its pharmacy department.
ADVERTISEMENT
"We are pleased that Maricopa Medical Center has selected the CDEX ValiMed unit as a tool for end product testing," said Malcolm Philips, CEO and Chairman of the Board for CDEX. "The Maricopa Medical Center offers a great venue to continue to improve our technology. Our list of nationally recognized clients who are using ValiMed continues to grow."
The ValiMed Patient Safety Solution uses light energy and a library of unique spectral fingerprints to validate IV drugs in solution. The device can validate that the correct drug and correct dose has been added to the medication during the compounding process.
About MIHS:
Maricopa Integrated Health System is headquartered in Phoenix. The cornerstone of the system is Maricopa Medical Center (MMC), a major teaching hospital with a history dating back more than 100 years. Best known for its critical care services, the hospital offers Level 1 trauma and intensive care for adults, babies and children. Two in-patient psychiatric care centers with nearly 200 beds provide services in behavioral medicine. The nation's second largest burn treatment facility, the Arizona Burn Center, located on the main hospital campus, treats more than 800 patients per year. Eleven family health care centers are located throughout the Valley, providing primary and specialty care ranging from well baby to HIV-AIDS patient services. For more information: www.mihs.org.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Jim Griffin or Jerry Blair at 301-881-0080 (cdexmanagement@cdex-inc.com).
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.
--------------------------------------------------------------------------------
Contact:
CDEX Inc., Rockville
Jim Griffin, 301-881-0080
AI
